医学
冲程(发动机)
转化研究
缺血
临床试验
神经科学
组织纤溶酶原激活剂
缺血性中风
重组组织纤溶酶原激活剂
疾病
食品药品监督管理局
病理生理学
神经学
重症监护医学
临床前研究
病理
心脏病学
内科学
药理学
医学物理学
心理学
机械工程
精神科
改良兰金量表
工程类
标识
DOI:10.1515/revneuro-2017-0076
摘要
Rodent and rabbit stroke models have been instrumental in our current understanding of stroke pathophysiology; however, translational failure is a significant problem in preclinical ischemic stroke research today. There are a number of different focal cerebral ischemia models that vary in their utility, pathophysiology of causing disease, and their response to treatments. Unfortunately, despite active preclinical research using these models, treatment options for ischemic stroke have not significantly advanced since the food and drug administration approval of tissue plasminogen activator in 1996. This review aims to summarize current stroke therapies, the preclinical experimental models used to help develop stroke therapies, as well as their advantages and limitations. In addition, this review discusses the potential for naturally occurring canine ischemic stroke models to compliment current preclinical models and to help bridge the translational gap between small mammal models and human clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI